ACADIA Pharmaceuticals Inc

ACAD NASDAQ
ACAD
ACADIA Pharmaceuticals Inc NASDAQ
 
Prossimi utili
EPS
Cap. di mercato
Div yield
P/E
Prossimi utili
EPS
Cap. di mercato
Div yield
P/E

Report finanziari ACAD

I conti di ACADIA Pharmaceuticals Inc, comprensivi di fatturato, spese, profitti e perdite

The total revenue of ACAD for the last quarter is 131.61M USD, and it's 14.23% higher compared to the previous quarter. The net income of Q3 21 is -14.46M USD.

TTM
Utile lordo
Totale ricavi
Cost of goods sold
Spese operative (escl. COGS)
Utile operativo
Non-operating income, total
Pretax income
Equity in earnings
Taxes
Non-controlling/minority interest
After tax other income/expense
Net income before discontinued operations
Discontinued operations
Utile netto
Dilution adjustment
Preferred dividends
Diluted net income available to common stockholders
Basic earnings per share (Basic EPS)
Diluted earnings per share (Diluted EPS)
Average basic shares outstanding
Diluted shares outstanding
EBITDA
EBIT
Totale spese operative